SHANG.FOS.PHARM.GR.H YC 1 Financial Flexibility Index
SHANG.FOS.PHARM.GR.H YC 1 financial flexibility index. SHANG.FOS.PHARM.GR.H YC 1 (08HH) has a Financial Flexibility Index of 0.17x as of December 2025. Free cash flow of €9.66 Billion (operating CF €5.21 Billion minus capex €4.45 Billion) represents 0% of total liabilities (€58.21 Billion). See 08HH cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
Financial flexibility index of SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025. Historical Financial Flexibility Index trend for SHANG.FOS.PHARM.GR.H YC 1 across 5 annual periods. Check SHANG.FOS.PHARM.GR.H YC 1 earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
SHANG.FOS.PHARM.GR.H YC 1 Financial Flexibility Index by Year (2021–2025)
SHANG.FOS.PHARM.GR.H YC 1 financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for SHANG.FOS.PHARM.GR.H YC 1. For the full cash flow conversion analysis, see 08HH cash flow metrics.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.17x | €9.66 Billion | €5.21 Billion | €58.21 Billion | ▲ +7.4% |
| 2024 | 0.15x | €8.89 Billion | €4.48 Billion | €57.53 Billion | ▲ +0.4% |
| 2023 | 0.15x | €8.75 Billion | €3.41 Billion | €56.85 Billion | ▼ -19.2% |
| 2022 | 0.19x | €10.11 Billion | €4.22 Billion | €53.05 Billion | ▼ -4.0% |
| 2021 | 0.20x | €8.91 Billion | €3.94 Billion | €44.93 Billion | — |